Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

ATAZANAVIR SULFATE;RITONAVIR;LAMIVUDINE;ZIDOVUDINE

ATAZANAVIR SULFATE;RITONAVIR;LAMIVUDINE;ZIDOVUDINE

Standard Dose
300MG;100MG;150MG;300MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: None (Tentative Approval)
Summary

Approval overview ATAZANAVIR SULFATE;RITONAVIR;LAMIVUDINE;ZIDOVUDINE is listed in Drugs@FDA under application 206041 (NDA).

Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient ATAZANAVIR SULFATE;RITONAVIR;LAMIVUDINE;ZIDOVUDINE Form and strength TABLET;ORAL - 300MG;100MG;150MG;300MG Sponsor MYLAN LABS LTD Submission history Latest submission status date: 2014-09-04 00:00:00.

Structured Monograph

Clinical summary

Approval overview ATAZANAVIR SULFATE;RITONAVIR;LAMIVUDINE;ZIDOVUDINE is listed in Drugs@FDA under application 206041 (NDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient ATAZANAVIR SULFATE;RITONAVIR;LAMIVUDINE;ZIDOVUDINE Form and strength TABLET;ORAL - 300MG;100MG;150MG;300MG Sponsor MYLAN LABS LTD Submission history Latest submission status date: 2014-09-04 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: None (Tentative Approval)
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.